Journal of Immunology Research / 2018 / Article / Tab 1

Review Article

Immunotherapy for Hepatocellular Carcinoma: Current Advances and Future Expectations

Table 1

Major immunotherapeutic approaches for HCC.

ApproachesSubsetsTargets and applications

ACTCIK cellsCIK with valproate, DC-CIK with TACE
NK cellsNK with K562-mb15-41BBL, sorafenib, and NKG2D
CAR T cells (generations 1–4)Targeting GPC3, targeting GPC3 and ASGR1

HCC vaccinesCell vaccinesHCC cells with GM-CSF
Antigen peptide vaccinesAFP, GPC3, SSX-2, NY-ESO-1, hTERT, HCA587, and MAGE-A
DC vaccinesTCL-loaded DCs with nifuroxazide

Immune checkpoint inhibitorsCTLA-4 inhibitorsTremelimumab, Tremelimumab with RFA
PD-1 inhibitorsNivolumab, Pembrolizumab, and Pidilizumab
PD-L1 inhibitorsPD-L1 inhibitor with DNMT1 inhibitor

Oncolytic virusesCVV, JX-594, GLV-1h68, and G47delta